1.
Indian J Dermatol Venereol Leprol
;
2016 Jan-Feb; 82(1): 79-81
Artigo
em Inglês
| IMSEAR
| ID: sea-170017
2.
Indian J Dermatol Venereol Leprol
;
2015 May-Jun; 81(3): 313-315
Artigo
em Inglês
| IMSEAR
| ID: sea-158332
3.
Indian J Dermatol Venereol Leprol
;
2006 Sep-Oct; 72(5): 373-5
Artigo
em Inglês
| IMSEAR
| ID: sea-52622
RESUMO
Imiquimod, an immune response modifier, is known to possess both anti-viral and anti-tumor effect. We report our experience of treating a large superficial spreading basal cell carcinoma with 5% imiquimod cream. A 65-year-old male had an asymptomatic, hyperpigmented, slowly progressive, indurated, 3 x 4 cm plaque on the left cheek for two months. Biopsy from the lesion showed features of basal cell carcinoma. The patient was treated with imiquimod 5% cream, topically three times a week for six months with complete resolution of the lesion and without any side-effects. There was no clinical or histological recurrence after three months of stopping the treatment.